WINDLAS1,135.00

Windlas Biotech Limited

· Pharma & Health
₹ CrorePeersHESTERBIOINDOCOSAIPARENTSYNCOMFPANACEABIONGLFINEHIKALJAGSNPHARMMcap ₹2,396 Cr
Annuals · FY-end closes
Compounded Growth
Annuals · CAGR %
1Y
CAGR
2Y
CAGR
Revenue+19.0+19.7
EBITDA+11.3+15.8
Net Income+9.0+6.9
Total Assets+19.3+20.4
Total Equity+14.8+13.6
Free Cash Flow+133.0-27.7
CAGR from filed annuals — needs positive start & end values.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.